Type 1 Diabetes Clinical Trials Enrolling in 2025

The Most Promising Type 1 Diabetes Trials Open Right Now

For the first time in decades, people living with Type 1 diabetes have genuine reason for optimism beyond better devices and insulin formulations. In 2025, a wave of clinical trials is targeting the root cause of T1D — the autoimmune destruction of insulin-producing beta cells — rather than simply managing the disease after the fact. Here's an honest look at what's enrolling, what the science shows, and what patients should realistically expect.

Stem Cell-Derived Beta Cell Therapies

Vertex Pharmaceuticals — VX-880 and VX-264
Vertex's VX-880 remains one of the most closely watched therapies in diabetes research. This infused therapy delivers stem cell-derived, fully differentiated islet cells into patients with T1D. Early Phase 1/2 results published in 2023 and updated through 2024 showed that patients achieved meaningful insulin production — with some reaching complete insulin independence — following treatment. The caveat: participants require lifelong immunosuppression to prevent rejection, similar to a traditional organ transplant.

To solve that problem, Vertex is simultaneously advancing VX-264, which packages the same stem cell-derived islets inside an immunoprotective encapsulation device designed to shield the cells from immune attack — potentially eliminating the need for immunosuppressants. VX-264 Phase 1/2 trials are actively enrolling in 2025. These are among the most significant trials in T1D history, and ClinicalTrials.gov (search NCT identifiers for VX-880 and VX-264) lists current enrollment details.

ViaCyte / CRISPR Therapeutics — VCTX210
ViaCyte, now part of Vertex's broader acquisition landscape, previously partnered with CRISPR Therapeutics to develop gene-edited islet cells (VCTX210) designed to evade immune detection without immunosuppression. While this program has faced development challenges and restructuring, its scientific approach continues to inform next-generation encapsulation and gene-editing strategies across the field.

Immune Modulation — Stopping the Attack Before It Starts

Teplizumab (Tzield) — Post-Approval Research
Provigil Pharmaceuticals' teplizumab became the first FDA-approved drug to delay the onset of Stage 3 Type 1 diabetes in at-risk individuals when it was approved in November 2022. The landmark TN-10 trial demonstrated that a 14-day course of teplizumab delayed clinical T1D diagnosis by a median of approximately 3 years in high-risk individuals with Stage 2 T1D (autoantibody-positive, abnormal glucose tolerance but not yet insulin-dependent). Now marketed as Tzield by Sanofi, ongoing studies in 2025 are evaluating repeated dosing, earlier intervention, and combination strategies.

The PROTECT Trial — Baricitinib
The PROTECT trial evaluated baricitinib — a JAK1/JAK2 inhibitor already approved for rheumatoid arthritis — in newly diagnosed T1D patients. Results published in The New England Journal of Medicine in 2023 showed that baricitinib significantly preserved beta cell function over 48 weeks compared to placebo, as measured by C-peptide levels. This is a meaningful finding because preserving even partial beta cell function can meaningfully improve glucose control and reduce hypoglycemia risk. Follow-on studies and combination trials are expected through 2025 and beyond.

Golimumab — ACCOMPLISH Trial
PharmaResearch Products' golimumab, a TNF-alpha inhibitor, showed in the Phase 2 ACCOMPLISH trial that it preserved C-peptide in newly diagnosed T1D patients aged 6–21. The FDA granted it Breakthrough Therapy Designation. Longer-term follow-up data is anticipated in 2025, and expanded trials may open for enrollment.

Combination and Prevention Approaches

The TrialNet network — a consortium of leading research centers funded by the NIH — continues to run multiple prevention and early-intervention trials across North America, Europe, and Australia. TrialNet screens relatives of people with T1D for autoantibodies and enrolls eligible participants into trials targeting immune tolerance before clinical diagnosis. Families with a T1D member should visit TrialNet's website and ClinicalTrials.gov to explore free antibody screening and trial eligibility.

Current Status (2025)

Stem cell therapies are real and producing real results in small patient populations — but they are not yet approved treatments. Teplizumab (Tzield) is the only FDA-approved disease-modifying therapy for T1D, and it applies to a specific at-risk population, not everyone with established T1D. Baricitinib and golimumab are promising but not yet approved for T1D specifically. The honest reality is that most patients living with T1D today will continue to depend on insulin, continuous glucose monitors, and insulin pumps — technologies covered and discussed at mdsdiabetes.com — for the foreseeable future. Disease-modifying therapies remain the horizon, not yet the standard of care.

Timeline — When Might These Become Available?

• Teplizumab (Tzield): Available NOW for Stage 2 T1D in at-risk individuals
• Baricitinib for T1D: Potentially 3–5 years pending larger Phase 3 trials
• VX-880 / VX-264: Earliest realistic approval window is 2027–2030, pending Phase 3 data
• Gene-edited islet cells without immunosuppression: Still in early-phase trials; likely a decade away

What This Means for Patients

If you or a family member has Type 1 diabetes, the most actionable steps today are: (1) Visit ClinicalTrials.gov and search "Type 1 diabetes" filtered by "enrolling" status to find trials near you. (2) Ask your endocrinologist whether you or at-risk family members qualify for TrialNet autoantibody screening — it's free. (3) If you were recently diagnosed with T1D, ask specifically about trials focused on newly diagnosed patients, where beta cell preservation trials tend to show the strongest results. (4) Don't delay optimizing your current management — better glucose control today protects your health while research matures. Use every tool available, from CGM to advanced insulin delivery systems.

The science has never moved faster. But honesty matters: today's patients need excellent daily management, and tomorrow's breakthroughs need volunteers willing to participate in trials.